The effects of combination treatment of IMM-101, a heat-killed whole cell preparation of Mycobacterium obuense (NCTC 13365) with Check Point Inhibitors in pre-clinical models.

Data from an ongoing collaboration between Immodulon Therapeutics and the laboratory of Prof. Andrew MacDonald at Manchester Collaborative Centre for Inflammation Research (University of Manchester, Manchester UK) on the effects of combination treatment of IMM‑101 (a heat-killed whole cell preparation of Mycobacterium obuense NCTC13365) with Check Point inhibitors in several preclinical models were presented at the 2016 Annual meeting of the Society for Immunotherapy (SITC).


On the basis of these promising results, formal clinical evaluation of IMM‑101 in combination treatment with anti-PD-1 treatment is being undertaken (EudraCT Number: 2016‑001459‑28)


Full title: The effects of combination treatment of IMM‑101, a heat-killed whole cell preparation of Mycobacterium obuense (NCTC 13365) with checkpoint inhibitors in pre-clinical models

Poster presented at the Annual Meeting of the SITC (Society for Immunotherapy of Cancer), held at National Harbour, Maryland (USA).

Date: 9-13 November 2016

Author[s]: James Crooks, Sheila Brown, Audrey Gauthier, Marc Hillairet de Boisferon, Andrew MacDonald and Laura Rosa Brunet.

Click here to view full poster
Click here to view full abstract